To view this email as a web page, click here.
 
NPs and PAs in Dermatology
 
COMMENTARY
 
Clinical Considerations for Derm NPs and PAs
image description here In this month's Clinical Considerations for NPs and PAs, the discussions surround the role of diet, combination therapies and cosmeceuticals in adolescent acne; the idea that total mole count at an earlier age could predict lifetime mole count and possibly melanoma risk; and, finally, how a uniform dataset could be tapped to learn more about psoriasis disease manifestations and treatment outcomes. Read my takeaways and the full stories below!
 
CLINICAL CONSIDERATIONS
 
Practice gaps in childhood acne treatment
In this article, Jonette Keri, M.D., Ph.D., identifies practice gaps between pediatrics and dermatology in the treatment of childhood acne. She points out that pediatricians do not initiate retinoids as first line therapy in the pre-adolescent population, and that pediatricians may be undertreating severe acne in their limited use of combination therapies. Dr. Keri also describes using a two- to four-week course of oral prednisone in the treatment of severe childhood acne.
Do you notice these trends in your patient population?
 
Changing moles in teens
Parents often bring children to our offices to "have their moles checked.” They often ask at what age annual mole checks should be initiated. The potential risk of a changing mole in an adult is very different than in a child. In fact, new and changing moles in children are exceedingly common according to Allan Halpern, M.D. It turns out that total mole count by age 13-14 may be the best predictor of number of moles by age 16-17.
Here, Dr. Halpern provides several pearls to improve our evaluation of moles in children.
 
Dermatologists collaborate on data-driven pediatric psoriasis research
Did you know that methotrexate is the most commonly used systemic therapy for pediatric psoriasis? This is great article that describes the importance of data driven research. Specifically, Amy S. Paller, M.D., M.S., describes how analysis of retrospective data collection can be used to improve future prospective research projects.
Read more about the percentage of pediatric patients who used TNF inhibitors.
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.